Heart protection study for people with heart disease and overweight
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 45 years or older.
- You have a body mass index (BMI) of 27 or higher, which means you are overweight or have obesity.
- You have a history of a heart attack, a stroke, or blocked arteries in your legs (peripheral artery disease).
- You have not had a heart attack, stroke, or major heart procedure in the past 60 days.
- You do not have type 1 diabetes, and if you have type 2 diabetes, your blood sugar control is moderate (A1C not above 10%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
This study tests whether people with obesity or overweight can safely and effectively give themselves the study medicine (called maridebart cafraglutide) at home using a pre-filled autoinjector pen. It is being studied as a weight-loss treatment for adults who have struggled to lose weight with diet and exercise alone.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
This study compares two versions of an investigational weight-loss injection to see if they are absorbed similarly. It is an early-stage trial for adults with a BMI of 25 or higher who want to help improve future treatments.
This study tests an investigational weight-loss medicine called Zenagamtide for people who have heart or blood vessel disease and are overweight or obese. The goal is to see if it can reduce heart-related risks compared to a placebo (a pill with no active medicine).
Hear when a new Atherosclerotic Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.